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See related article on page 633. In this issue of The Journal of Thoracic and Cardiovascular Surgery, theCAMIAT Investigators1 present an interesting post hoc analysis of amio-darone used in 82 patients undergoing cardiac surgery who were part of alarger trial that examined prophylactic amiodarone therapy in patients atrisk for sudden death after myocardial infarction. This post hoc analysis hasa problem common to all such analyses; namely the initial research pro-
posal was not specifically designed or powered to answer the questions that were
raised in the secondary analysis. Nevertheless, the small number of prospective
trials (especially prospective randomized trials) of amiodarone used in the setting of
cardiac surgery make this information useful for placing the risks of amiodarone
into perspective with its benefits.
Crystal and associates found no differences in the 7- and 30-day mortalities,
duration of intensive care unit stay, risk of atrial or ventricular fibrillation, and risk
of pulmonary complications between those who did and did not receive amiodarone
before a cardiac operation. However, there was a higher rate of postoperative
intra-aortic balloon pump use among the patients treated with amiodarone. Thus this
study supports the notion that amiodarone has a negative inotropic or vasodilatory
effect but refutes other commonly held beliefs regarding the drug’s adverse effects
on heart rate and pulmonary function. It should also be noted that the doses of
amiodarone were relatively low, and the median time between cessation of amio-
darone dosing and surgery was 15 days in this trial.
I remember many years ago discussing the perioperative use of amiodarone with
a friend from Europe. He believed that the side effects of amiodarone were greatly
outweighed by its efficacy. I disagreed and thought that amiodarone would never be
widely used in the United States because of its acute and chronic toxicities. It is time
for me to “eat crow.” Amiodarone is currently the most commonly prescribed
antiarrhythmic drug in Europe, Latin America, and North America, and its use
increased by 20% from 1997 to 1998.2 As pointed out by the CAMIAT Investiga-
tors, the issue of how to manage patients receiving short- or long-term amiodarone
therapy is one that surgeons must face on a regular basis. An alternative approach
to operating on patients fully loaded with amiodarone is to defer surgery until
amiodarone has been eliminated from the system.3 For most patients this is imprac-
tical because of the large volume of distribution and consequent long elimination
half-life of amiodarone (30 to 60 days), as well as because of the threat of
arrhythmia recurrence while amiodarone levels are falling. It is timely to reflect on
what have we learned during the past decade and define as best we can the risks for
patients receiving amiodarone therapy who face a cardiac (or pulmonary) surgical
procedure.
The answers presented in this editorial are based on evolving information that is
by definition incomplete. Moreover, amiodarone is typically used in patients with
life-threatening arrhythmias in the setting of important heart disease. Dissecting out
the toxic effect of amiodarone from the morbidity and mortality related to the
disease process itself is difficult. This difficulty suggests that we should rely more
heavily on information derived from prospective randomized trials (even if it comes
from a secondary analysis of the data), rather than information from any other
source.
Acute postoperative pulmonary toxicity associated with amiodarone therapy and
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exposure to high concentrations of inspired oxygen appears
to be a sporadic event that usually follows an inexorably
worsening course culminating in death.4 The evidence that
this occurs and is related to oxygen dose is based on animal
studies and clinical observations. Fortunately, limiting in-
spired oxygen concentration during and after surgery ap-
pears to ameliorate this complication. Vigilant care of pa-
tients in the current era may explain why this problem was
not found in the CAMIAT analysis or in another post hoc
analysis of a prospective randomized trial.5
Other adverse events, such as low cardiac output or
hypotension requiring perioperative intra-aortic balloon
counterpulsation, may occur more commonly among pa-
tients treated with amiodarone, particularly if the therapy is
long term and high dose. However, the mortality associated
with this morbidity appears low according to limited infor-
mation from prospective randomized trials as well as retro-
spective studies that account for the influence of the pa-
tients’ underlying heart disease.5,6 This observation is made
recognizing the limitation of extrapolating from relatively
small study groups to accurately define the etiology for
adverse events in a group of patients with many potential
reasons for complications.
Another issue to consider is the prophylactic use of
amiodarone to minimize the occurrence of postoperative
atrial fibrillation. Several studies have shown that amioda-
rone can decrease the prevalence of postoperative atrial
fibrillation, although the details of optimal dosing and du-
ration of treatment have not yet been worked out.7 Toxicity
of amiodarone was not found to be a problem in these
studies, possibly because the dosage was relatively low and
the drug was given for a short period of time. Thus it seems
that the cost of this prophylaxis and its efficacy in relation-
ship to alternatives for prevention of atrial fibrillation, such
as -antagonists, are more important questions to answer
than questions of toxicity.
Cardiac surgery is a dynamic specialty. We develop
novel therapies, incorporate useful ideas and materials from
other fields, and respond to the constantly changing chal-
lenges posed by our patients. The typical cycle for respond-
ing to challenge or change is one of recognition, skepticism
and observation, further evaluation, and eventually consen-
sus. There is not yet consensus regarding the issue of risks
and benefits of amiodarone therapy in cardiac surgery, but
there is mounting information to indicate that amiodarone is
not as hazardous as was initially thought. With appropriate
vigilance, it can be used with a reasonable degree of safety
to provide an important antiarrhythmic benefit.
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